Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Dyne Therapeutics, Inc. announced the appointment of Erick J. Lucera as its new Chief Financial Officer, effective March 31, 2025. Lucera brings over 30 years of experience in the life sciences ...

Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would look for ways ...

Dyne Therapeutics, a clinical-stage company focused on therapeutics for genetically driven neuromuscular diseases, announced that it will present new clinical data from its Phase 1/2 ACHIEVE trial ...

Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows ...

In January, Dyne Therapeutics revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101, the company’s lead candidate, in patients with myotonic dystrophy type 1 (DM1).

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD). This designation is pivotal for developing DYNE ...

The latest price target for Dyne Therapeutics (NASDAQ:DYN) was reported by HC Wainwright & Co. on May 9, 2025. The analyst firm set a price target for $38.00 expecting DYN to rise to within 12 ...

Dyne Therapeutics' earnings per share surpassed both Oppenheimer and consensus estimates, coming in at ($0.70) compared to the projected ($0.72). In response to these developments, Piper Sandler ...

Dyne therapeutics chief scientific officer sells shares worth $80,539 Open in App ...